Valiant Laboratories: The financial results for the period ended September 30, 2026
Valiant Laboratories (VALIANTLAB) filed a disclosure titled "The financial results for the period ended September 30, 2026". The company is valued at about ₹697 crore.
What happened
Valiant Laboratories (VALIANTLAB) filed a disclosure with the exchanges on 2 November 2026 at 06:59 PM titled "The financial results for the period ended September 30, 2026".
Company snapshot
Valiant Laboratories is a micro-cap company, with a market value of about ₹697 crore.
The stock last traded at ₹128.4, against a 52-week range of ₹49.51–₹141.4 (9.2% below the high).
Before this filing the shares had moved +5.1% over the month and +111.4% over three months. Average daily turnover over the last 20 sessions was about ₹0.85 crore.
Promoters held 74.94% at the end of Q1 FY27. Foreign institutions owned 0.00% and domestic institutions 0.00%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 47 | 1.8 | 0.42 |
| Q2 FY26 | 46 | 0.2 | 0.04 |
| Q3 FY26 | 52 | -7.1 | -1.3 |
| Q4 FY26 | 92 | 1.8 | 0.32 |
| Q1 FY27 | 115 | 21.1 | 3.89 |
What history shows
BCEIE's records show 1 previous results filing from the company since May 2026.
Market-wide, 10,143 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 2 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.